NR4A1 and breast carcinoma: The majority of patients had hormone receptor (HR) positive (55%) breast cancer with 30.5% of patients having stage 1 breast cancer, 50.8% having stage II breast cancer and 18.6% having stage III breast cancer (Table 1).